JBIO
XNASJade Biosciences, Inc. Common Stock
Basic Materials · Pharmaceutical Preparations
$21.68
+0.84 (+4.05%)
15-min delayed
Drag to pan · Scroll to zoom · Hover for OHLC
Snapshot
Loading metrics…
About Jade Biosciences, Inc. Common Stock
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Employees
55
Country
US
IPO Date
2025-04-29
Recent News
What's going on in today's after hours session
ChartMill · 12h ago
Jade Biosciences To Present Phase 1 JADE101 Data In Conference Call On June 1, 2026 At 8:00 a.m. ET
Benzinga · 17h ago
BTIG Reiterates Buy on Jade Biosciences, Maintains $39 Price Target
Benzinga · 3d ago
Jade Biosciences Doses First Patient In Phase 1 Clinical Study Of JADE201; Anticipates Interim First-In-Human Data Next Year
Benzinga · 3d ago
COMMUNITY · $JBIO0 theses
POST YOUR TAKE →Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.